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Anorexia–cachexia syndrome develops during the advanced stages of various chronic
diseases in which patients exhibit a decreased food intake, weight loss, and muscle tissue
wasting. For these patients, this syndrome is a critical problem leading to an increased rate
of morbidity and mortality. The present pharmacological therapies for treating anorexia–
cachexia have limited effectiveness. The Japanese herbal medicine rikkunshito is often
prescribed for the treatment of anorexia and upper gastrointestinal (GI) disorders. Thus,
rikkunshito is expected to be beneﬁcial for the treatment of patientswith anorexia–cachexia
syndrome. In this review, we summarize the effects of rikkunshito and its mechanisms of
action on anorexia–cachexia. Persistent loss of appetite leads to a progressive depletion
of body energy stores, which is frequently associated with cachexia. Consequently,
regulating appetite and energy homeostasis is critically important for treating cachexia.
Ghrelin is mainly secreted from the stomach, and it plays an important role in initiating
feeding, controlling GI motility, and regulating energy expenditure. Recent clinical and
basic science studies have demonstrated that the critical mechanism of rikkunshito
underlies endogenous ghrelin activity. Interestingly, several components of rikkunshito
target multiple gastric and central sites, and regulate the secretion, receptor sensitization,
and degradation of ghrelin. Rikkunshito is effective for the treatment of anorexia, body
weight loss, muscle wasting, and anxiety-related behavior. Furthermore, treatment with
rikkunshito was observed to prolong survival in an animal model of cachexia. The use of
a potentiator of ghrelin signaling, such as rikkunshito, may represent a novel approach for
the treatment of anorexia–cachexia syndrome.
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INTRODUCTION
Anorexia–cachexia syndrome is characterized by decreased food
intake, hypoalbuminemia, weight loss, and muscle tissue wast-
ing (Tan et al., 2014). This syndrome is observed in patients
with advanced stages of various chronic diseases (von Haehling
and Anker, 2010), and is a cause of their increased rate of
morbidity and mortality (Evans et al., 2008). The treatment of
anorexia–cachexia is, therefore, critically important for improv-
ing quality of life (QOL) in patients. The onset and development
of anorexia–cachexia syndrome is typically associated with an
increase in pro-inﬂammatory cytokine levels (Plata-Salaman,
2000). Therefore, megestrol acetate (Ruiz Garcia et al., 2013) and
glucocorticoids are options for the pharmacological therapy of
anorexia–cachexia; however, they have limited efﬁcacy (Nelson,
2000; Jatoi et al., 2002). Recently, ghrelin, because of its orexigenic
activity, has been suggested as beneﬁcial to treat anorexia–cachexia
syndrome (Molﬁno et al., 2014). Ghrelin is involved in eliciting
feeding, controlling gastrointestinal (GI) motility, and regulating
energy expenditure andbodyweight. Thus, clinical trials of ghrelin
analogs in cancer cachexia are ongoing (Currow and Abernethy,
2014; Pietra et al., 2014).
Kampo medicine is Japanese traditional herbal medicine stan-
dardized with respect to the quality and quantity of ingredients
under the Japanese Ministry of Health, Labour, and Welfare.
It has been developed through clinical and laboratory stud-
ies based on Western-adopted experiment-based approaches (Yu
et al., 2006). Rikkunshito, a type of Kampo medicine, is widely
prescribed as a remedy for various upper GI syndromes. The
adverse drug reaction reports involve hepatobiliary disorders,
pseudoaldosteronism, and myopathy. Rikkunshito is manufac-
tured by spray-drying a hot water extract of a mixture of eight
varieties of the following crude drugs: Atractylodis lanceae rhi-
zoma (4.0 g), Ginseng radix (4.0 g), Pinelliae tuber (4.0 g),
Poria (4.0 g), Zizyphi fructus (2.0 g), Aurantii nobilis peri-
carpium (2.0 g), Glycyrrhizae radix (1.0 g), and Zingiberis rhizoma
(0.5 g). There is increasing scientiﬁc evidence supporting the
clinical use of rikkunshito (Takeda et al., 2012). It has been
demonstrated that rikkunshito improves anorexia and cachexia,
and the improvement is mediated by promoting endogenous
ghrelin activity (Suzuki et al., 2012). A better understanding
of rikkunshito’s mechanism of action and its active compo-
nents will contribute to the development of new therapies to
improve QOL and potentially to prolong survival in patients
with anorexia–cachexia syndrome. The present article reviews
the pharmacological effects and clinical beneﬁts of rikkunshito
in anorexia–cachexia syndrome.
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CLINICAL APPLICATIONS OF RIKKUNSHITO FOR GI
DISORDERS
Functional dyspepsia, which is classiﬁed as a functional GI disor-
der (FGID), is deﬁned as a disease with dyspeptic symptoms, such
as postprandial fullness, early satiety, and epigastric burning, and
there is no evidence of a structural disease that is likely to explain
the symptoms (Tack et al., 2006). Patients with functional dyspep-
sia exhibit gastric dysmotility, such as delayed gastric emptying
(Stanghellini et al., 1996) and impaired gastric accommodation
(Tack et al., 1998).
Several clinical studies have demonstrated the effectiveness of
rikkunshito in the treatment of GI disorders, including anorexia
and gastric dysmotility. Tatsuta and Iishi (1993) reported that
the administering rikkunshito, which is named Liu-Jun-Zi-Tang
in China, for 7 days accelerated gastric emptying and reduced
GI symptoms in 22 patients with chronic idiopathic dyspepsia.
Placebo treatment, administered to 20 patients, produced no sig-
niﬁcant effects (Tatsuta and Iishi, 1993). A large-scale comparative
clinical study of 235 patients with dysmotility-like dyspepsia was
conducted (Harasawa et al., 1998). Rikkunshito-treated patients
(n = 118) were given 2.5 g of rikkunshito three times a day
for 2 weeks, and placebo-treated patients (n = 117) were given
2.5 g of placebo, including 2.5% rikkunshito, as control. As a
result, the dysmotility-like dyspepsia generalized improvement
rate (DDGI) was signiﬁcantly higher in the rikkunshito-treated
group than in the placebo group. Moreover, rikkunshito was
effective in improving anorexia in patients with severe or mod-
erate dyspeptic symptoms. Recently, a multicenter, randomized,
placebo-controlled, parallel-group trial of rikkunshito in 247
patients with functional dyspepsia was conducted (Suzuki et al.,
2014). The administration of 2.5 g of rikkunshito three times a
day for 8weeks reduced dyspepsia; epigastric painwas signiﬁcantly
improved and postprandial fullness tended to improve compared
to the placebo treatment group. There were no severe adverse
events in either group.
Gastroesophageal reﬂux disease (GERD) is often associated
with decreased upper GI motility. The therapeutic effects of
rikkunshito were reported in proton pump inhibitor (PPI)-
refractory patients with GERD or non-erosive reﬂux disease
(NERD). Four-week treatment with rikkunshito (7.5 g/day)
in combination with the PPI rabeprazole (RPZ) signiﬁcantly
decreased the frequency scale for the symptoms of GERD (FSSG
score) in 104 patients with GERD, which is similar to the decrease
observed in response to treatment with a double dose of RPZ
(Tominaga et al., 2012). In a randomized, placebo-controlled,
double-blind clinical trial for 242 patients with PPI-refractory
NERD, treatment for 4 or 8 weeks with rikkunshito (7.5 g/day)
improved their mental component summary (MCS) scores in the
Short-Form Health Survey-8 (SF-8), which was especially more
effective in patients with a low body mass index (<22). Moreover,
rikkunshito signiﬁcantly improved the acid-related dysmotility
symptoms of FSSG in female and elderly patients (≥65 years;
Sakata et al., 2014; Tominaga et al., 2014).
Additionally, several clinical reports have provided evidence
for the therapeutic effects of rikkunshito on GI symptoms and
function (Kusunoki et al., 2010; Morita et al., 2012; Gunji et al.,
2013; Tokashiki et al., 2013; Uehara et al., 2013).
BASIC STUDIES OF RIKKUNSHITO ON ANOREXIA AND GI
DYSFUNCTION
Physical or psychological stress can cause anorexia and functional
disorders in the upperGI tract. Several basic studies of rikkunshito
on stress-related anorexia in animals have been reported. Saegusa
et al. (2011) constructed a stress model by transferring mice from
group-housed cages to individual cages, which are novel envi-
ronments for mice. The mice stressed by the novel environment
exhibited a decrease in food intake 1 and 3 h after stress, which
was suppressed by pre-treatment with rikkunshito (500 mg/kg,
p.o.) 1 h before the stress (Saegusa et al., 2011). Various psy-
chological factors contribute to decreased food intake among the
elderly population. Nahata et al. (2013) reported that exposure of
aged mice (79–80 weeks old) to a novel environment markedly
decreased food intake compared with that of young mice (6 weeks
old). Rikkunshito (1000 mg/kg, p.o.) administration attenuated
the decrease in 24-h food intake in stressed aged mice (Nahata
et al., 2013).
Urocortin 1 (UCN), a stress hormone, acts on corticotropin-
releasing factor (CRF) receptors in the brain and induces anorexia.
Yakabi et al. (2011) reported that rikkunshito (1000 mg/kg, p.o.)
restored the reduction of food intake in rats with intracerebroven-
tricular administration of UCN (300 pmol). Additionally, the
following studies demonstrated that the alpha-2 adrenergic recep-
tor pathway contributes to the associated reduction in food intake
(Yakabi et al., 2014).
The efﬁcacy of rikkunshito in the treatment of GI disorders
was observed in patients with dysmotility-like dyspepsia (Hara-
sawa et al., 1998). Nahata et al. (2014) also reported the effect of
rikkunshito on gastric function in an acute restraint stress mouse
model. Mice exposed to restraint stress for 60 min exhibited
delayed gastric emptying. Gastric motility, which was wirelessly
measured using a strain gage force transducer, was also decreased
by restraint stress. Rikkunshito (250 mg/kg, p.o.) administration
improved the restraint stress-induced delayed gastric emptying
and decreased postprandial gastric contractions (Nahata et al.,
2014). These ﬁndings suggest that rikkunshito ameliorates several
types of stress-induced anorexia and gastric dysmotility.
RIKKUNSHITO’S MECHANISM OF ACTION
GHRELIN
Ghrelin is a 28-amino-acid peptide that is mainly secreted from
the X/A-like cells in the stomach, and several tissues, including
the brain, have small levels of ghrelin. It acts as a natural lig-
and for the growth hormone secretagogue receptor (GHS-R).
Acylation of Ser-3 by the addition of n-octanoic acid via the
polytopic membrane-bound enzyme ghrelin O-acyltransferase
(GOAT) is essential for the biological activity of ghrelin via the
GHS-R (Kojima et al., 1999; Gnanapavan et al., 2002; Yang et al.,
2008).
Ghrelin plays role not only in growth hormone secretion
(Kojima et al., 1999) but also in initiating feeding as an appetite
stimulant (Nakazato et al., 2001). The plasma ghrelin levels
increase in response to prolonged fasting and they decrease rapidly
after feeding, suggesting that peripheral ghrelin is signiﬁcant
for appetite regulation (Cummings et al., 2001; Tschop et al.,
2001). Ghrelin signals are transmitted to the nuclei of the solitary
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tract via the vagal afferent pathway and they activate the orex-
igenic neuropeptides neuropeptide Y (NPY) and agouti-related
peptide (AgRP) neurons in the hypothalamic arcuate nucleus
(ARC), resulting in appetite stimulation (Date et al., 2002; Chen
et al., 2004). Additionally, ghrelin has much broader physiologic
functions (Kojima and Kangawa, 2005), including controlling
GI motility (Fujino et al., 2003), regulating energy expenditure
(Asakawa et al., 2001), and suppressing inﬂammation (Dixit et al.,
2004; Granado et al., 2005).
The central or peripheral administration of ghrelin strongly
stimulates food intake and increases fat mass, leading to weight
gain in animals (Tschop et al., 2000; Asakawa et al., 2001; Nakazato
et al., 2001). The intravenous administration of ghrelin in healthy
humans increased visual analog scores for appetite and energy
intake froma buffet lunch by 28% (Wren et al., 2001). These results
suggest the possible clinical applications of ghrelin as a potent
stimulator of appetite.
PROMOTION OF GHRELIN ACTIVITY BY RIKKUNSHITO
The inhibitory effects of rikkunshito on anorexia and gastric
dysmotility are thought to be involved in promoting endoge-
nous ghrelin activity. Takeda et al. (2008) demonstrated that
rikkunshito ameliorated anorexia in rats treated with cisplatin
by inhibiting the decrease of ghrelin levels in the plasma. This
is the ﬁrst report showing that rikkunshito stimulates ghrelin
secretion in rats (Takeda et al., 2008). Selective serotonin reuptake
inhibitors (SSRIs), including fenﬂuramine, decreased the plasma
ghrelin levels and changed GI motilities in rats. The oral admin-
istration of rikkunshito to fenﬂuramine-treated rats increased the
plasma ghrelin levels, food intake, and gastric emptying rate
and improved GI dysmotility. The positive effects of rikkun-
shito on dyspeptic symptoms disappeared after treatment with
the GHS-R antagonist (D-Lys3)-GHRP-6, suggesting it mediates
the ghrelin signal (Fujitsuka et al., 2009). The ghrelin-mediated
appetite-stimulatory effect of rikkunshito was also observed in
novel-environment-stressed mice (Saegusa et al., 2011) and UCN-
treated rats (Yakabi et al., 2011). Intra-gastric administration of
rikkunshito (4 g) is reported to induce fasted phasic contrac-
tions in the duodenum and jejunum and to accelerate gastric
emptying in dogs. The plasma ghrelin level 150 min after the
administration of rikkunshito was signiﬁcantly higher than the
control value (Yanai et al., 2013). Wang et al. (2014) reported that
rikkunshito enhanced the fasting plasma levels of ghrelin and alle-
viated the delayed gastric empty in L-dopa/carbidopa-treatednaïve
and Parkinson’s disease rats, partially through ghrelin-related
mechanisms.
Ghrelin is predominantly produced in gastric X/A-like cells and
activates the orexigenic neuropeptides NPY/AgRP in the hypotha-
lamus through the GHS-R in the vagal afferent terminal in the
stomach (Date et al., 2002). Rikkunshito-treated rats exhibited ele-
vated gene expression of gastric ghrelin and hypothalamic NPY.
The afferent activity of the gastric vagus nerve decreased with
the intravenous administration of ghrelin. A similar effect was
observed with the intraduodenal administration of rikkunshito
(1,000 mg/kg; Asakawa et al., 2001; Fujitsuka et al., 2011). Gastric
ghrelin signals induced by the administration of ghrelin (10 ng,
i.v.) or rikkunshito (1,000 mg/kg, i.d.) stimulated the efferent
activities of both the gastric and the celiac branches of the vagus
nerve, which is involved in GI motor activities (Fujino et al., 2003).
These ﬁndings suggest that rikkunshito activates the ghrelin signal
in the vagus nerve. Additionally, gastric vagotomy eliminated the
stimulatory effect of ghrelin (10 ng, i.v.) on the efferent activi-
ties of the gastric vagus nerve but did not inﬂuence the effects of
rikkunshito (1,000 mg/kg, i.d.), suggesting rikkunshito acts in part
through the GHS-R in the hypothalamus.
Clinical trials have revealed a signiﬁcant increase in the con-
centration of circulating ghrelin with rikkunshito. Matsumura
et al. (2010) demonstrated that the administration of rikkunshito
(7.5 g per day) for 2 weeks increased the plasma ghrelin levels in
21 healthy volunteers. Takiguchi et al. (2013) demonstrated a sig-
niﬁcant attenuation of GI symptoms after treatment with 2.5 g
of rikkunshito for 4 weeks in 25 patients who had undergone
gastrectomy. The mean ratio of the acyl-/total ghrelin concentra-
tion increased after rikkunshito administration (Takiguchi et al.,
2013). Arai et al. (2012) conducted a parallel, randomized, con-
trolled trial of rikkunshito or domperidone for 4 weeks for 27
patients with functional dyspepsia. Upper GI symptoms based
on the Gastrointestinal Symptom Rating Scale (GSRS) score were
ameliorated in both groups, but the efﬁcacy of rikkunshito was
accompanied by an increase in the ghrelin levels (Arai et al.,
2012).
TARGET MOLECULES AND ACTIVE COMPONENTS OF
RIKKUNSHITO
Rikkunshito was reported to regulate ghrelin secretion, ghrelin
receptor sensitization, and ghrelin degradation, suggesting that
rikkunshito synergistically promotes endogenous ghrelin activity
(Uezono et al., 2012). As shownTable 1, some targetmolecules and
active components of rikkunshito involved in these effects were
identiﬁed. Summary of the rikkunshito’s mechanism of action
was shown Figure 1.
SEROTONIN 2b/2c RECEPTORS
The central serotonin (5-HT) system is implicated in the pro-
cesses of meal satiation and satiety (Vickers et al., 2001, 2003;
Halford et al., 2007). Takeda et al. (2008) demonstrated that 5-HT
produced during treatment with cisplatin stimulates the 5-HT2b
receptor in the stomach and the 5-HT2c receptor in the central
nervous system, resulting in decreased plasma ghrelin. Hep-
tamethoxyﬂavone, hesperetin (an aglycon form of hesperidin),
and isoliquiritigenin,which are components of rikkunshito, antag-
onize 5-HT2b/2c receptors and stimulate ghrelin secretion in
cisplatin-treated rats. Fenﬂuramine decreased plasma ghrelin and
changed ghrelin-mediated GI motor activities through the cen-
tral 5-HT2c receptor. The oral administration of hesperidin
to fenﬂuramine-treated rats restored GI dysmotility (Fujitsuka
et al., 2009). These ﬁndings suggest that these components of
rikkunshito augment ghrelin secretion through antagonizing the
5-HT2b/c receptors.
Nahata et al. (2013) demonstrated that exposure of aged
mice to a novel environment up-regulated hypothalamic 5-HT2c
receptor mRNA expression. 5-HT2c receptor signaling enhance-
ment and the subsequent activation of the CRF-corticosterone
pathway were involved in novelty-induced hypophagia in aged
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Table 1 |Target molecules and active components of rikkunshito.
Target molecules Active components
(Crude drug)
Structure Reference
5-HT2b/2cR 3,3′,4′,5,6,7,8-
Hep-
tamethoxyfkvone
(Aurantii nobilis
pericarpium)
Takeda et al. (2008)
Hesperetin an
aglycon form of
hesperidin
(Aurantii nobilis
pericarpium)
Takeda et al. (2008)
Isoliquiritigenin
(Glycyrrhizae
radix)
Takeda et al. (2008)
GHS-R Atractylodin
(Atractylodis
lanceae rhizoma)
Fujitsuka et al. (2011)
Ghrelin deacylating enzymes 10-Gingerol
(Zingiberis
rhizoma)
Sadakane et al. (2011)
mice. The 5-HT2c receptor antagonist SB242084 or rikkun-
shito administration attenuated the decrease in food intake and
increased corticosterone levels in stressed aged mice (Nahata et al.,
2013).
Additionally, in vitro studies using fura-2 microﬂuorome-
try have revealed that rikkunshito inﬂuences the effect of 5-HT
on hypothalamic neurons. Administration of 10−5 mol/L 5-HT
increased the cytosolic Ca2+ concentration in single neurons
isolated from the paraventricular nucleus (PVN) of rats. These
changes were inhibited by the administration of 100 μg/mL of
rikkunshito to the PVN neurons, 83% of which subsequently
demonstrated immunoreactivity to CRF (Fujitsuka et al., 2011).
Administration of 5-HT increased the cytosolic Ca2+ concen-
tration in ARC neurons, and 80% of the 5-HT-responsive neu-
rons were immunoreactive to pro-opiomelanocortin (POMC).
Rikkunshito and isoliquiritigenin counteracted 5-HT-induced
5-HT2c receptor-mediated Ca2+ signaling in POMC neurons
(Arai et al., 2013). These results suggest that the inhibition of the
5-HT 2c receptor expressed on CRF neurons (Heisler et al., 2007)
or POMC neurons (Heisler et al., 2003) could be responsible for
rikkunshito’s attenuation of anorexia.
GHRELIN RECEPTOR
Growth hormone secretagogue receptors are located in periph-
eral several tissues and central neurons, including NPY neurons.
Ghrelin increases the cytosolic Ca2+ concentration in the NPY
neurons of the hypothalamic ARC (Kohno et al., 2003), and this
effect is linked to stimulation of appetite (Kohno et al., 2007).
Compared to 10−12 mol/L ghrelin administration, pretreatment
with rikkunshito enhanced the ghrelin-induced increase in cytoso-
lic Ca2+ levels in isolated fura-2-loaded rat ARC neurons, which
were subsequently shown to be NPY neurons by immunocyto-
chemistry (Fujitsuka et al., 2011). Furthermore, Ca2+ imaging
analysis using ﬂuorescence of G-CAMP2 revealed that rikkunshito
(100 μg/mL) had no effect on the cytosolic Ca2+ concentration;
however, it enhanced the duration of the cytosolic Ca2+ con-
centration increased by 10−7 mol/L ghrelin in GHS-R-expressing
COS cells. Rikkunshito also increased the binding activity of
[125I]-ghrelin to the GHS-R.
To identify active component of rikkunshito, the 43 compounds
(100 μmol/L) contained in rikkunshito were screened. As a result,
atractylodin showed a marked increase in ghrelin/GHS-R binding
activity. Atractylodin also sustained the ghrelin-induced cytosolic
Ca2+ increase in GHS-R-expressing cells (Fujitsuka et al., 2011).
These results suggest that atractylodin is active component of
rikkunshito, which potentiates the action of ghrelin by presumably
sensitizing the ghrelin receptor.
Nahata et al. (2012) demonstrated that ghrelin increased antral
motility in sham-operated rats but not in GERD rats. However,
in GERD rats treated with rikkunshito, a signiﬁcant increase in
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FIGURE 1 | Summary of the mechanism of action by some
ingredients of rikkunshito. Rikkunshito synergistically promotes
endogenous ghrelin activity. The ingredients of rikkunshito such as
heptamethoxyﬂavone and hesperetin (an aglycon form of hesperidin),
antagonize 5-HT2b/2c receptors in the stomach and the hypothalamus,
which are related to ghrelin secretion. Atractylodin activates ghrelin
receptors in the stomach and the hypothalamus. 10-Gingerol inhibits
ghrelin deacylating enzymes in various tissues, including the stomach.
The potentiation of ghrelin signaling pathways may be responsible for
rikkunshito’s attenuation of anorexia. POMC, pro-opiomelanocortin; GHS-R,
ghrelin receptor; NST, nucleus tractus solitarii; NPY, neuropeptide Y; AgRP,
agouti-related peptide.
antralmotility by ghrelin was observed (Nahata et al., 2012). These
ﬁndings suggest that the physiological functions of endogenous
ghrelin are potentiated by rikkunshito acting on GHS-R signaling,
which may be mediated by atractylodin, an active component of
rikkunshito.
GHRELIN DEGRADING ENZYME
Sadakane et al. (2011) reported that rikkunshito increased the acyl-
to desacyl-ghrelin (A/D) ratio in plasma from cisplatin-treated
rats. Several components of rikkunshito have inhibitory activities
against ghrelin deacylating enzymes. 10-gingerol, an active com-
ponent of rikkunshito, inhibited exogenous ghrelin deacylation in
rats. These results suggest that the increase in the plasma ghrelin
level by rikkunshito ismediated, at least in part, through inhibiting
the ghrelin degrading enzyme (Sadakane et al., 2011).
CACHEXIA
PATHOGENESIS OF ANOREXIA–CACHEXIA SYNDROME
Anorexia–cachexia syndrome develops during the advanced stages
of various chronic diseases, such as malignant cancer, chronic
heart failure, chronic kidney disease, and chronic obstructive pul-
monary disease (von Haehling and Anker, 2010). This syndrome
results in a decreased QOL and increased morbidity and mortality.
Cachexia is diagnosed by the presence of weight loss exceeding 5%
within the previous 3–12 months, anorexia, loss of skeletal muscle,
and biochemical abnormalities, such as increased inﬂammatory
markers, anemia, and hypoalbuminemia (Evans et al., 2008). In
particular, anorexia is very important in the diagnosis and treat-
ment of cachexia-associated weight loss because a persistent loss
of appetite leads to a progressive depletion of body energy stores
(Argiles et al., 2010).
Cytokines participate in the development and/or progression
of anorexia–cachexia (Plata-Salaman, 2000). Cancer cachec-
tic animals exhibit increased plasma levels of cytokines, such
as interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis
factor-α (TNF-α), and leukemia inhibitory factor (LIF), which are
either produced by cancer cells or released by the host immune
system in response to the cancer (Mori et al., 1991; Inui, 2002;
Ebrahimi et al., 2004; Perboni and Inui, 2006; Tisdale, 2009).
These cytokines in the brain or circulation augment the release of
anorexigenic hormones, including 5-HT, leptin, cholecystokinin
(CCK), peptides derived from the glucagon precursor, and insulin
(Shintani et al., 1993; Laviano et al., 2000). Increased 5-HT con-
centration in the hypothalamus is demonstrated in animals with
cancer (Wang et al., 2003). Megestrol acetate and glucocorticoids
are options for the pharmacological therapy of anorexia–cachexia,
but they have limited effectiveness (Nelson, 2000; Jatoi et al.,
2002).
ROLE OF GHRELIN ON CACHEXIA
Circulating ghrelin levels are reported to increase in under-
weight patients with malignancy-associated cachexia (Shimizu
et al., 2003; Garcia et al., 2005) and tumor-bearing animals
(Terawaki et al., 2014), suggesting a failure of the adaptive feeding
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response by endogenous ghrelin (Schwartz et al., 1995; Schwartz
and Seeley, 1997; Flier, 1998). The plasma ghrelin levels were
higher in tumor-bearing rats than in free-fed normal rats, but they
were signiﬁcantly lower than in pair-fed normal rats. Decreases in
the hypothalamic expression of NPY andAgRP were also observed
in tumor-bearing rats compared to pair-fed controls. Therefore,
cancer anorexia–cachexia is characterized as a decrease in ghrelin
signaling with both ghrelin insufﬁciency and resistance, which is
mediated by excessive hypothalamic interactions of 5-HT andCRF
through the 5-HT2c receptor (Fujitsuka et al., 2011). Administra-
tion of ghrelin (Hanada et al., 2003) or GHS-R agonist (Currow
and Abernethy, 2014; Pietra et al., 2014) can overcome resistance
to the appetite-stimulating effects of the endogenous ghrelin and
improve food intake andweight gain inhumanandanimal subjects
with cachexia.
Additionally, ghrelin inhibits the production of anorectic
proinﬂammatory cytokines, including IL-1β, IL-6, and TNF-α
(Dixit et al., 2004). DeBoer et al. (2007) demonstrated that ghrelin-
treated animals with cancer cachexia have a signiﬁcant increase
in the expression of AgRP and NPY with decreased expression
of the IL-1 receptor-I transcript in the hypothalamus. Chronic
kidney disease is associated with an increase in inﬂammatory
cytokines, resulting in cachexia with muscle loss. Ghrelin-treated
nephrectomized animals had a decrease in circulating inﬂamma-
tory cytokines and IL-1 receptor expression in the brainstem.
Ghrelin treatment in uremia results in improved leanmass accrual,
which is in part due to suppressed muscle proteolysis and possibly
related to anti-inﬂammatory effects (Deboer et al., 2008; Suzuki
et al., 2013). Ghrelin administration reduced lung inﬂammation,
protected alveolar epithelial cells, and ameliorated lung ﬁbrosis
in a bleomycin (BLM)-induced acute lung injury model in mice
(Imazu et al., 2011). The combination of orexigenic and anti-
inﬂammatory actions suggests that ghrelin has beneﬁts in the
treatment of cachexia.
ANTI-CACHECTIC EFFECT OF RIKKUNSHITO
Increasing evidence from experimental animal models has shown
that rikkunshito, which synergistically promotes endogenous
ghrelin activity, ameliorates several types of cachexia. These ﬁnd-
ings suggest that rikkunshito may be more effective for ghrelin
resistance such as cancer anorexia–cachexia than treatment of
ghrelin or GHS-R agonists.
Rikkunshito improved anorexia, gastrointesitinal dysmotil-
ity, muscle wasting, and anxiety-related behavior in AH-130
hepatoma-bearing rats (Fujitsuka et al., 2011). The authors
observed anorexia 5 days after intraperitoneal injection of tumor
in rats, but the administration of rikkunshito (1000 mg/kg,
p.o.) increased food intake for 6 h in tumor-bearing rats. The
appetite-stimulating effect of rikkunshito was blocked by the
ghrelin receptor antagonist (D-Lys3)-GHRP-6 (2 μmol/kg, i.v.),
suggesting that endogenous ghrelin plays a role in rikkunshito’s
effects. The frequency of phase III-like contractions in the antrum
and duodenum, which is fasting motor activity mediated by
ghrelin signaling, decreased in tumor-bearing rats. Rikkunshito
(1,000 mg/kg) gradually restored the phase III-like contractions.
Additionally rikkunshito (500 mg/kg, p.o. twice daily) prolonged
survival in tumor-bearing rats, and this effect was enhanced by
the concomitant administration of cisplatin (CDDP; 1 mg/kg, i.p.,
twice a week from 6 days).
Stomach cancer patients have the highest incidence of cachexia.
Terawaki et al. (2014) examined the effects of rikkunshito in a
novel stomach cancer cachexia model by implanting nude rats
with 85As2 cells. The 85As2 cells line is derived from peritoneal
metastasis of the orthotopically implanted human stomach cancer
cell line MKN45cl85 and produces LIF,which is a known cachectic
factor. This cachexia model involves signiﬁcant anorexia, weight
loss, body composition changes, increased inﬂammatory marker
levels, and low serum albumin levels, fulﬁlling the cachexia diag-
nostic criteria. Rikkunshito (orally administered twice daily at
1,000 mg/kg/day for 7 days starting 14 days after the implanta-
tion of 85As2 cells in rats) resulted in increased food and water
intake rates. Furthermore, rikkunshito substantially alleviated
body weight loss and reductions in body compositions, such as
fat-free mass, total body water, and total musculature weight,
in the 85As2-induced cachexia rat. The anti-cachectic effects of
rikkunshito are not related to tumor regression or plasma LIF
levels. Therefore, these effects of rikkunshito are likely medi-
ated by activating the GHS-R-NPY/AgRP orexigenic signaling
pathway.
Tsubouchi et al. (2014a) examined the impact of rikkunshito
on BLM-induced pulmonary ﬁbrosis in mice as a model of pul-
monary cachexia. In BLM mice, the administration of rikkunshito
(1000 mg/kg, p.o.) for 14 days ameliorated the decrease in body
weight and food intake as well as pulmonary inﬂammation and
ﬁbrosis. In BLM-treated ghrelin−/− and Ghsr−/− mice, rikkun-
shito improved pulmonary inﬂammation, while failing to inhibit
the BLM-associated decrease in food intake and body weight
(Tsubouchi et al., 2014b). Therefore, the effects of rikkunshito on
anorexia and weight loss were assumed to be mediated by ghrelin
signaling.
The beneﬁcial effect of rikkunshito on survival was also
demonstrated in human patients through a retrospective analysis.
Pancreatic cancer patients with ascites (stage III and IV) received
gemcitabine or gemcitabine plus rikkunshito. Themedian survival
of pancreatic cancer patients with ascites who were treated with
gemcitabine was signiﬁcantly prolonged by the administration of
rikkunshito (Fujitsuka et al., 2011). Future, large-scale clinical tri-
als are required to determine the efﬁcacy and safety of rikkunshito
on cancer cachexia.
CONCLUSION
Cachexia syndrome develops during the advanced stages of vari-
ous chronic diseases and leads to a decreased QOL and increased
rate of morbidity and mortality in patients. The Kampo medicine
rikkunshito is prescribed for various upper GI syndromes, such
as anorexia, and is very important in the treatment of cachexia-
associated weight loss. Clinical and basic studies demonstrate that
rikkunshito ameliorates anorexia and cachexia, which may be
mediated by synergistically promoting endogenous ghrelin activ-
ity by several components of rikkunshito. The use of a ghrelin
potentiator, such as rikkunshito, is expected to represent a novel
approach for the treatment of anorexia–cachexia syndrome,which
is characterized as a decrease in ghrelin signaling with both ghrelin
insufﬁciency and resistance.
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